At least 14 million children are expected to face disruptions to essential nutrition support and services in 2025 because of ...

ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry MomentumSARASOTA, Fla.

If we want to turn these short-term gains into sustainable change, we must fully unleash the potential of methadone-assisted ...

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...

BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology ...

Eleonora Teplinsky, MD, a medical oncologist specializing in breast and gynecologic cancers, has seen unregulated and ...

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A ...

BioAtla Inc (BCAB) reports promising clinical progress and strategic initiatives, despite facing financial constraints and operational challenges.

ImmunoPrecise Antibodies Ltd. ( NASDAQ: IPA) Q3 2025 Earnings Conference Call March 28, 2025 10:30 AM ET Jennifer Bath - Chief Executive Officer and President Joseph Scheffler - Interim Chief ...

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our ...

Full-year results and business updateClinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized ...